Equillium, Inc. is a biotechnology company developing novel therapies for severe autoimmune and inflammatory disorders. Its primary candidate, EQ504, is a preclinical AhR modulator intended for ulcerative colitis and GI diseases, with potential for inflammatory lung diseases. EQ302 is a preclinical, oral, bi-specific inhibitor of IL-15 and IL-21 targeting celiac disease and other GI indications. The company acquired EQ504 via Ariagen in 2024 and EQ302 via Bioniz in 2022.
expected 2027-01-04
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-25 | 2025-12-31 | 0001193125-26-124143 | EDGAR | 87K words |
| 2025-03-27 | 2024-12-31 | 0000950170-25-045726 | EDGAR | 97K words |
| 2024-03-25 | 2023-12-31 | 0000950170-24-035919 | EDGAR | 101K words |
| 2023-03-23 | 2022-12-31 | 0000950170-23-009492 | EDGAR | 99K words |
| 2022-03-23 | 2021-12-31 | 0000950170-22-004407 | EDGAR | 92K words |
| 2021-03-24 | 2020-12-31 | 0001564590-21-015103 | EDGAR | 96K words |
| 2020-03-26 | 2019-12-31 | 0001564590-20-013207 | EDGAR | 106K words |
| 2019-03-27 | 2018-12-31 | 0001564590-19-009580 | EDGAR | 83K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-11-12 | 2026-09-30 | 0001193125-26-458443 | EDGAR | 61K words |
| 2026-08-13 | 2026-06-30 | 0001193125-26-349235 | EDGAR | 59K words |
| 2025-11-13 | 2025-09-30 | 0001193125-25-280202 | EDGAR | 65K words |
| 2025-08-14 | 2025-06-30 | 0000950170-25-108834 | EDGAR | 69K words |
| 2025-05-14 | 2025-03-31 | 0000950170-25-071389 | EDGAR | 64K words |
| 2024-11-13 | 2024-09-30 | 0000950170-24-126322 | EDGAR | 72K words |
| 2024-08-08 | 2024-06-30 | 0000950170-24-093949 | EDGAR | 73K words |
| 2024-05-09 | 2024-03-31 | 0000950170-24-056960 | EDGAR | 69K words |
| 2023-11-08 | 2023-09-30 | 0000950170-23-061108 | EDGAR | 70K words |
| 2023-08-09 | 2023-06-30 | 0000950170-23-040583 | EDGAR | 69K words |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021236 | EDGAR | 68K words |
| 2022-11-14 | 2022-09-30 | 0000950170-22-025052 | EDGAR | 72K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-11-12 | 0001193125-26-458379 | EDGAR | 1K words |
| 2026-10-26 | 0001193125-26-432158 | EDGAR | 1K words |
| 2026-10-05 | 0001193125-26-414364 | EDGAR | 1K words |
| 2026-08-13 | 0001193125-26-349182 | EDGAR | 2K words |
| 2026-03-25 | 0001193125-26-124107 | EDGAR | 2K words |
| 2026-03-13 | 0001193125-26-105083 | EDGAR | 18K words |
| 2025-11-13 | 0001193125-25-280173 | EDGAR | 2K words |
| 2025-10-06 | 0001193125-25-231860 | EDGAR | 2K words |
| 2025-09-19 | 0001193125-25-209068 | EDGAR | 1K words |
| 2025-09-04 | 0000950170-25-113023 | EDGAR | 1K words |
164 total filings indexed. 134 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001746466 |
| Ticker | EQ |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.equilliumbio.com |
| Listed | 2018-10-12 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/EQ (~200 tokens, structured JSON with cryptographic provenance)